Stock ALACT ACTICOR BIOTECH SAS
Add to a list
To use this feature you must be a member
Log inSign up

Acticor Biotech SAS Share Price

Equities

ALACT

FR0014005OJ5

Biotechnology & Medical Research

End-of-day quote Euronext Paris
Other stock markets
 03:30:00 26/04/2024 am IST 		5-day change 1st Jan Change
0.336 EUR +24.44% Intraday chart for Acticor Biotech SAS -91.94% -88.41%
26/04 Acticor Biotech: rebound from the previous day's tumble CF
25/04 Acticor Biotech: Phase 2/3 study fails CF

Financials

Sales 2023 * - Sales 2024 * - Capitalization 4.41M 4.73M 395M
Net income 2023 * -15M -16.07M -1.34B Net income 2024 * -13M -13.93M -1.16B EV / Sales 2023 * -
Net Debt 2023 * 5.2M 5.57M 465M Net Debt 2024 * 10.8M 11.57M 966M EV / Sales 2024 * -
P/E ratio 2023 *
-0.28 x
P/E ratio 2024 *
-0.4 x
Employees 29
Yield 2023 *
-
Yield 2024 *
-
Free-Float 100%
More Fundamentals * Assessed data

Chart Acticor Biotech SAS

Dynamic Chart

Latest news about Acticor Biotech SAS

Acticor Biotech: rebound from the previous day's tumble CF
Acticor Biotech: Phase 2/3 study fails CF
Acticor Biotech SAS Announces Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment CI
Acticor Biotech: phase 2/3 results expected in May CF
Acticor Biotech Will Present the Clinical Results of Its Phase 2/3 Actisave Study in the Treatment of Stroke At Esoc 2024 CI
Acticor Biotech: falls after capital increase CF
Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development MT
The University of Birmingham and Acticor Biotech Announce the First Patient Treated in LIBERATE, First Clinical Trial Evaluating Glenzocimab for Heart Attack CI
Acticor: 'we are delighted to observe the market's reaction'. CF
Acticor Biotech continues to soar, hopes for stroke treatment CF
Acticor Biotech Announces Publication of ACTIMIS Clinical Study Results in the Lancet Neurology Journal CI
Acticor: capital increase at a significant discount CF
Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results MT
ACTICOR BIOTECH Announces Timely Completed Patient Recruitment of Its Phase 2/3 Study in Stroke CI
Acticor Biotech SAS Reports Earnings Results for the Half Year Ended June 30, 2023 CI
More news

Press releases Acticor Biotech SAS

ACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment BU
Acticor Biotech will Present the Clinical Results of Its Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024 BU
Acticor Biotech Completes a Capital Increase for a Total Gross Amount of 8 Million Euros BU
The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attack AQ
Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke AQ
More press releases

News in other languages on Acticor Biotech SAS

Acticor Biotech : rebond après la dégringolade de la veille
Acticor Biotech : échec de l'étude de phase 2/3
Le marché devient un peu timbré
En Direct des Marchés : Hermès, Schneider, Atos, Carrefour, Casino, Sanofi, STMicro, Meta...
ACTICOR BIOTECH : Résultats principaux de l’étude de phase 2/3 ACTISAVE dans le traitement de l’AVC
More news

Quotes and Performance

1 day+24.44%
1 week-91.94%
Current month-89.53%
1 month-89.53%
3 months-92.11%
6 months-91.27%
Current year-88.41%
More quotes

Highs and lows

1 week
0.27
Extreme 0.27
4.10
1 month
0.27
Extreme 0.27
4.21
Current year
0.27
Extreme 0.27
5.32
1 year
0.27
Extreme 0.27
6.22
3 years
0.27
Extreme 0.27
11.00
5 years
0.27
Extreme 0.27
11.00
10 years
0.27
Extreme 0.27
11.00
More quotes

Managers and Directors - Acticor Biotech SAS

Managers TitleAgeSince
Gilles Avenard FOU
 Founder - 26/13/26
Eric Cohen DFI
 Director of Finance/CFO - -
Adeline Meilhoc CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Gilles Avenard FOU
 Founder - 26/13/26
Catherine Boule BRD
 Director/Board Member - -
Alain Munoz CHM
 Chairman 75 15/21/15
More insiders

Quotes

Date Price Change Volume
26/24/26 0.336 +24.44% 1,658,205
25/24/25 0.27 -92.64% 811,570
24/24/24 3.67 -5.66% 15,700
23/24/23 3.89 +1.83% 6,270
22/24/22 3.82 -8.39% 36,758

End-of-day quote Euronext Paris, April 26, 2024

More quotes

Company Profile

Acticor Biotech is specialized in the research and development of medicines for the treatment of thrombotic diseases, in particular acute ischemic strokes and pulmonary embolisms. The group has one product in Phase II/III clinical development (Glenzocimab).
Sector
Biotechnology & Medical Research
Calendar
30/04/2024 - Q4 2023 Earnings Release
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.336 EUR
Average target price
10 EUR
Spread / Average Target
+2,876.19%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ACTICOR BIOTECH SAS Stock Acticor Biotech SAS
-88.41% 4.71M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.52% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.82% 95.28B
ARGENX SE Stock argenx SE
+1.46% 22.15B
BIONTECH SE Stock BioNTech SE
-15.24% 21.02B
GENMAB A/S Stock Genmab A/S
-8.58% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.38% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.19% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.67% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ALACT Stock